top of page


Dive into the Biopharma Space

Stay up-to-date on major biopharma news, deeper dives into specific companies and biopharma themes, and how it all relates to biopharma partners.

Biopharma Approvals, New Data, M&A activity, and more...

First U.S. NASH/MASH approval + 12 updates...👇

Madrigal Pharmaceuticals 

🎯 FDA Approved Rezdiffra™ (resmetirom) for the treatment of NASH (MASH) w/ moderate to advanced liver fibrosis.


🎯 FDA approved Praluent® (alirocumab) injection treating children with genetic form of high cholesterol.

Mirum Pharma

🎯 LIVMARLI received FDA approval for the treatment of cholestatic pruritus in patients w/ progressive familial intrahepatic cholestasis.


🎯 FDA approved TEVIMBRA® treating esophageal squamous cell carcinoma after prior chemotherapy.

Bristol Myers Squibb 

🎯 Received FDA approval for Breyanzi® as the first and only CAR-T cell therapy for adults with r/r CLL or SLL.


🎯 FDA Onco-drugs AdCom votes 12-2 in favor of Imetelstat treating transfusion-dependent anemia in patients with lower-risk MDS.

Aquestive Therapeutics 

🔬 Anaphylm™ (epinephrine) sublingual film met primary and secondary endpoints in pivotal Ph3 study.  

Acadia Pharmaceuticals

🔬 Top-line results reported from Ph3 ADVANCE-2 trial of Pimavanserin in negative symptoms of schizophrenia.


🔬 Promising results with the discovery of novel anti-cancer small molecule structure.


Merck & Harpoon Therapeutics

🤝 Merck completed the acquisition of Harpoon Therapeutics

AstraZeneca & Amolyt

🤝 AstraZeneca will acquire Amolyt to expand its late-stage rare disease pipeline.

Aeterna Zentaris & Ceapro 

🤝 Merger approved by security holders.


Interested in these updates? Get the full update each week → 


March 11-15, 2024

Article History:

RF, DV (03/15/24)


bottom of page